CSL Limited Sponsored ADR (CSLLY)
OTC PINK OTC PINK Primary 
CSL Limited (CSLLY) Analyst/Investor Day Prepared Remarks Transcript
CSL Limited (OTCQX:CSLLY) Analyst/Investor Day November 4, 2025 6:00 PM EST Company Participants Fiona Mead - Company Secretary & Head of Corporate Governance Paul McKenzie - MD, CEO & Executive Director Dave Ross - Senior VP & GM of Seqirus Presentation Fiona Mead Company Secretary & Head of Corporate Governance Hello. I'm Fiona Mead, CSL's Company Secretary.
CSL Limited (CSLLY) Q4 2025 Earnings Call Transcript
CSL Limited (OTCQX:CSLLY) Q4 2025 Earnings Conference Call August 18, 2025 8:00 PM ET Company Participants Andy Schmeltz - Executive Vice President of CSL Behring Chris Cooper - Head of Investor Relations Herve Gisserot - Senior VP & GM of Vifor Joy Carolyn Linton - Chief Financial Officer Paul F. McKenzie - MD, CEO & Executive Director Conference Call Participants Andrew Goodsall - MST Financial Services Pty Limited, Research Division Andrew Paine - CLSA Limited, Research Division Craig Wong-Pan - RBC Capital Markets, Research Division David A.
CSL Limited (CSLLY) Q2 2025 Earnings Call Transcript
CSL Limited (OTCQX:CSLLY) Q2 2025 Results Earnings Conference Call February 10, 2025 7:00 PM ET Company Participants Chris Cooper - Vice President and Head of Investor Relations Paul McKenzie - Chief Executive Officer and Managing Director John Levy - Interim Chief Financial Officer Joy Linton - Interim Executive Vice President, CSL Behring Dave Ross - Senior Vice President and General Manager, CSL Seqirus Hervé Gisserot - Senior Vice President and General Manager, CSL Vifor Conference Call Participants Lyanne Harrison - Bank of America Davinthra Thillainathan - Goldman Sachs David Stanton - Jefferies David Low - J.P. Morgan Andrew Goodsall - MST Marquee Sacha Krien - Evans & Partners Saul Hadassin - Barrenjoey Craig Wong-Pan - RBC Capital Markets Steve Wheen - Jarden Andrew Paine - CLSA Laura Sutcliffe - UBS Mathieu Chevrier - Citigroup Shane Storey - Wilsons Advisory and Stockbroking Limited Thomas Wakim - Bell Potter Securities David Bailey - Macquarie Securities Shane Ponraj - Morningstar Operator Thank you for standing by and welcome to the CSL Limited Half Year Financial Results.
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
CSL Limited CSLLY and uniQure Inc QURE announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dezaparvovec-drlb) for adults hemophilia B patients.
CSL Limited: Good Results Overshadowed By Below-Expectations Guidance
CSLLY's FY 2024 results were good thanks to the outperformance of the Behring segment; the company's net profit in constant currency terms grew +15% YoY to $2.91 billion, which was in line with expectations. But CSL Limited's FY 2025 earnings guidance was a miss, and this is likely attributable to the expected underperformance of the Seqirus and Vifor segments. My rating for CSL Limited stays as a Hold, as the company's strong FY 2024 earnings growth was obscured by its disappointing FY 2025 bottom line guidance.
CSL Limited (CSLLY) Q4 2024 Earnings Call Transcript
CSL Limited (OTCQX:CSLLY) Q4 2024 Results Conference Call August 12, 2024 9:00 PM ET Company Participants Joy Linton - CFO Chris Cooper - Head, IR Paul McKenzie - MD, CEO & Executive Director Ken Lim - Chief Strategy Officer Conference Call Participants Lyanne Harrison - Bank of America Saul Hadassin - Barrenjoey Gretel Janu - Evans & Partners Steve Wheen - Jarden Andrew Goodsall - MST Marquee David Low - JPMorgan Craig Wong-Pan - RBC David Stanton - Jefferies Laura Sutcliffe - UBS Mathieu Chevrier - Citi David Bailey - Macquarie Joy Linton Good morning, everyone, and welcome to CSL's Financial Year 2024 Results Presentation. I'm Joy Linton, CSL's Chief Financial Officer.
Australia's CSL falls on weaker-than-expected annual profit forecast
Shares of CSL Ltd fell more than 3% on Tuesday after the Australian biotech firm forecast an annual profit that was higher than a year earlier but below market consensus.
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
